Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes.

Wanda K. Nicholson, Lisa Wilson, Catherine Takacs Witkop, Kesha Baptiste-Roberts, Wendy Bennett, Shari Bolen, Bethany B. Barone, Sherita Hill Golden, Tiffany L. Gary, Donna M Neale, Eric B Bass

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: We focused on four questions: What are the risks and benefits of an oral diabetes agent (i.e., glyburide), as compared to all types of insulin, for gestational diabetes? What is the evidence that elective labor induction, cesarean delivery, or timing of induction is associated with benefits or harm to the mother and neonate? What risk factors are associated with the development of type 2 diabetes after gestational diabetes? What are the performance characteristics of diagnostic tests for type 2 diabetes in women with gestational diabetes? DATA SOURCES: We searched electronic databases for studies published through January 2007. Additional articles were identified by searching the table of contents of 13 journals for relevant citations from August 2006 to January 2007 and reviewing the references in eligible articles and selected review articles. REVIEW METHODS: Paired investigators reviewed abstracts and full articles. We included studies that were written in English, reported on human subjects, contained original data, and evaluated women with appropriately diagnosed gestational diabetes. Paired reviewers performed serial abstraction of data from each eligible study. Study quality was assessed independently by each reviewer. RESULTS: The search identified 45 relevant articles. The evidence indicated that: Maternal glucose levels do not differ substantially in those treated with insulin versus insulin analogues or oral agents. Average infant birth weight may be lower in mothers treated with insulin than with glyburide. Induction at 38 weeks may reduce the macrosomia rate, with no increase in cesarean delivery rates. Anthropometric measures, fasting blood glucose (FBG), and 2-hour glucose value are the strongest risk factors associated with development of type 2 diabetes. FBG had high specificity, but variable sensitivity, when compared to the 75-gm oral glucose tolerance test (OGTT) in the diagnosis of type 2 diabetes after delivery. CONCLUSIONS: The evidence suggests that benefits and a low likelihood of harm are associated with the treatment of gestational diabetes with an oral diabetes agent or insulin. The effect of induction or elective cesarean on outcomes is unclear. The evidence is consistent that anthropometry identifies women at risk of developing subsequent type 2 diabetes; however, no evidence suggested the FBG out-performs the 75-gm OGTT in diagnosing type 2 diabetes after delivery.

Original languageEnglish (US)
Pages (from-to)1-96
Number of pages96
JournalEvidence report/technology assessment
Issue number162
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

Gestational Diabetes
Type 2 Diabetes Mellitus
Postpartum Period
Insulin
Blood Glucose
Fasting
Glyburide
Mothers
Glucose Tolerance Test
Therapeutics
Induced Labor
Glucose
Anthropometry
Routine Diagnostic Tests
Birth Weight
Research Personnel
Newborn Infant
Databases
Sensitivity and Specificity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes. / Nicholson, Wanda K.; Wilson, Lisa; Witkop, Catherine Takacs; Baptiste-Roberts, Kesha; Bennett, Wendy; Bolen, Shari; Barone, Bethany B.; Golden, Sherita Hill; Gary, Tiffany L.; Neale, Donna M; Bass, Eric B.

In: Evidence report/technology assessment, No. 162, 03.2008, p. 1-96.

Research output: Contribution to journalArticle

Nicholson, Wanda K. ; Wilson, Lisa ; Witkop, Catherine Takacs ; Baptiste-Roberts, Kesha ; Bennett, Wendy ; Bolen, Shari ; Barone, Bethany B. ; Golden, Sherita Hill ; Gary, Tiffany L. ; Neale, Donna M ; Bass, Eric B. / Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes. In: Evidence report/technology assessment. 2008 ; No. 162. pp. 1-96.
@article{c187efd593f14ba99ac79f78428439b0,
title = "Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes.",
abstract = "OBJECTIVES: We focused on four questions: What are the risks and benefits of an oral diabetes agent (i.e., glyburide), as compared to all types of insulin, for gestational diabetes? What is the evidence that elective labor induction, cesarean delivery, or timing of induction is associated with benefits or harm to the mother and neonate? What risk factors are associated with the development of type 2 diabetes after gestational diabetes? What are the performance characteristics of diagnostic tests for type 2 diabetes in women with gestational diabetes? DATA SOURCES: We searched electronic databases for studies published through January 2007. Additional articles were identified by searching the table of contents of 13 journals for relevant citations from August 2006 to January 2007 and reviewing the references in eligible articles and selected review articles. REVIEW METHODS: Paired investigators reviewed abstracts and full articles. We included studies that were written in English, reported on human subjects, contained original data, and evaluated women with appropriately diagnosed gestational diabetes. Paired reviewers performed serial abstraction of data from each eligible study. Study quality was assessed independently by each reviewer. RESULTS: The search identified 45 relevant articles. The evidence indicated that: Maternal glucose levels do not differ substantially in those treated with insulin versus insulin analogues or oral agents. Average infant birth weight may be lower in mothers treated with insulin than with glyburide. Induction at 38 weeks may reduce the macrosomia rate, with no increase in cesarean delivery rates. Anthropometric measures, fasting blood glucose (FBG), and 2-hour glucose value are the strongest risk factors associated with development of type 2 diabetes. FBG had high specificity, but variable sensitivity, when compared to the 75-gm oral glucose tolerance test (OGTT) in the diagnosis of type 2 diabetes after delivery. CONCLUSIONS: The evidence suggests that benefits and a low likelihood of harm are associated with the treatment of gestational diabetes with an oral diabetes agent or insulin. The effect of induction or elective cesarean on outcomes is unclear. The evidence is consistent that anthropometry identifies women at risk of developing subsequent type 2 diabetes; however, no evidence suggested the FBG out-performs the 75-gm OGTT in diagnosing type 2 diabetes after delivery.",
author = "Nicholson, {Wanda K.} and Lisa Wilson and Witkop, {Catherine Takacs} and Kesha Baptiste-Roberts and Wendy Bennett and Shari Bolen and Barone, {Bethany B.} and Golden, {Sherita Hill} and Gary, {Tiffany L.} and Neale, {Donna M} and Bass, {Eric B}",
year = "2008",
month = "3",
language = "English (US)",
pages = "1--96",
journal = "Evidence report/technology assessment",
issn = "1530-4396",
publisher = "Agency For Health Care Policy And Research",
number = "162",

}

TY - JOUR

T1 - Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes.

AU - Nicholson, Wanda K.

AU - Wilson, Lisa

AU - Witkop, Catherine Takacs

AU - Baptiste-Roberts, Kesha

AU - Bennett, Wendy

AU - Bolen, Shari

AU - Barone, Bethany B.

AU - Golden, Sherita Hill

AU - Gary, Tiffany L.

AU - Neale, Donna M

AU - Bass, Eric B

PY - 2008/3

Y1 - 2008/3

N2 - OBJECTIVES: We focused on four questions: What are the risks and benefits of an oral diabetes agent (i.e., glyburide), as compared to all types of insulin, for gestational diabetes? What is the evidence that elective labor induction, cesarean delivery, or timing of induction is associated with benefits or harm to the mother and neonate? What risk factors are associated with the development of type 2 diabetes after gestational diabetes? What are the performance characteristics of diagnostic tests for type 2 diabetes in women with gestational diabetes? DATA SOURCES: We searched electronic databases for studies published through January 2007. Additional articles were identified by searching the table of contents of 13 journals for relevant citations from August 2006 to January 2007 and reviewing the references in eligible articles and selected review articles. REVIEW METHODS: Paired investigators reviewed abstracts and full articles. We included studies that were written in English, reported on human subjects, contained original data, and evaluated women with appropriately diagnosed gestational diabetes. Paired reviewers performed serial abstraction of data from each eligible study. Study quality was assessed independently by each reviewer. RESULTS: The search identified 45 relevant articles. The evidence indicated that: Maternal glucose levels do not differ substantially in those treated with insulin versus insulin analogues or oral agents. Average infant birth weight may be lower in mothers treated with insulin than with glyburide. Induction at 38 weeks may reduce the macrosomia rate, with no increase in cesarean delivery rates. Anthropometric measures, fasting blood glucose (FBG), and 2-hour glucose value are the strongest risk factors associated with development of type 2 diabetes. FBG had high specificity, but variable sensitivity, when compared to the 75-gm oral glucose tolerance test (OGTT) in the diagnosis of type 2 diabetes after delivery. CONCLUSIONS: The evidence suggests that benefits and a low likelihood of harm are associated with the treatment of gestational diabetes with an oral diabetes agent or insulin. The effect of induction or elective cesarean on outcomes is unclear. The evidence is consistent that anthropometry identifies women at risk of developing subsequent type 2 diabetes; however, no evidence suggested the FBG out-performs the 75-gm OGTT in diagnosing type 2 diabetes after delivery.

AB - OBJECTIVES: We focused on four questions: What are the risks and benefits of an oral diabetes agent (i.e., glyburide), as compared to all types of insulin, for gestational diabetes? What is the evidence that elective labor induction, cesarean delivery, or timing of induction is associated with benefits or harm to the mother and neonate? What risk factors are associated with the development of type 2 diabetes after gestational diabetes? What are the performance characteristics of diagnostic tests for type 2 diabetes in women with gestational diabetes? DATA SOURCES: We searched electronic databases for studies published through January 2007. Additional articles were identified by searching the table of contents of 13 journals for relevant citations from August 2006 to January 2007 and reviewing the references in eligible articles and selected review articles. REVIEW METHODS: Paired investigators reviewed abstracts and full articles. We included studies that were written in English, reported on human subjects, contained original data, and evaluated women with appropriately diagnosed gestational diabetes. Paired reviewers performed serial abstraction of data from each eligible study. Study quality was assessed independently by each reviewer. RESULTS: The search identified 45 relevant articles. The evidence indicated that: Maternal glucose levels do not differ substantially in those treated with insulin versus insulin analogues or oral agents. Average infant birth weight may be lower in mothers treated with insulin than with glyburide. Induction at 38 weeks may reduce the macrosomia rate, with no increase in cesarean delivery rates. Anthropometric measures, fasting blood glucose (FBG), and 2-hour glucose value are the strongest risk factors associated with development of type 2 diabetes. FBG had high specificity, but variable sensitivity, when compared to the 75-gm oral glucose tolerance test (OGTT) in the diagnosis of type 2 diabetes after delivery. CONCLUSIONS: The evidence suggests that benefits and a low likelihood of harm are associated with the treatment of gestational diabetes with an oral diabetes agent or insulin. The effect of induction or elective cesarean on outcomes is unclear. The evidence is consistent that anthropometry identifies women at risk of developing subsequent type 2 diabetes; however, no evidence suggested the FBG out-performs the 75-gm OGTT in diagnosing type 2 diabetes after delivery.

UR - http://www.scopus.com/inward/record.url?scp=43749098749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749098749&partnerID=8YFLogxK

M3 - Article

C2 - 18457474

AN - SCOPUS:43749098749

SP - 1

EP - 96

JO - Evidence report/technology assessment

JF - Evidence report/technology assessment

SN - 1530-4396

IS - 162

ER -